Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome
Achille Ambrosetti(International Extranodal Lymphoma Study Group), G. Pizzolo(University of Verona), Fabrizio Vinante(University of Verona), L. Morosato(University of Verona), Gianpaolo Nadali(Azienda Ospedaliera Universitaria Integrata Verona), Stefano Carlini(University of Verona), D. De Sabata(University of Verona), G. Perona(University of Verona), Sergio Romagnani(Unknown), Gianpietro Semenzato(University of Padua), Enrico Maggi(Bambino Gesù Children's Hospital), Dino Veneri, Paola Parronchi(Azienda Ospedaliero-Universitaria Careggi), Giuseppe Todeschini(University of Pisa), Marco Chilosi
Cited by 35
Related Papers
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
|Arthritis & Rheumatology|2021|165
<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres
|British Journal of Haematology|2002|149